Abstract
Anhedonia, the inability to feel pleasure, and amotivation, the lack of motivation, are two prominent negative symptoms of schizophrenia, which contribute to the poor social and occupational behaviors in the patients. Recently growing evidence shows that anhedonia and amotivation are tied together, but have distinct neural correlates. It is important to note that both of these symptoms may derive from deficient functioningof the reward network. A further analysis into the neuroimaging findings of schizophrenia shows that the neural correlates overlap in the reward network including the ventral striatum, anterior cingulate cortex and orbitofrontal cortex. Other neuroimaging studies have demonstrated the involvement of the default mode network in anhedonia. The identification of aspecific deficit in hedonic and motivational capacity may help to elucidatethe mechanisms behind social functioning deficits in schizophrenia, and may also lead to more targetedtreatment of negative symptoms.
Keywords: Amotivation, anhedonia, anterior cingulate cortex, orbitofrontal cortex, reward system, schizophrenia, ventral striatum.
Graphical Abstract
Current Neuropharmacology
Title:Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System
Volume: 13 Issue: 6
Author(s): Jung Suk Lee, Suwon Jung, Il Ho Park and Jae-Jin Kim
Affiliation:
Keywords: Amotivation, anhedonia, anterior cingulate cortex, orbitofrontal cortex, reward system, schizophrenia, ventral striatum.
Abstract: Anhedonia, the inability to feel pleasure, and amotivation, the lack of motivation, are two prominent negative symptoms of schizophrenia, which contribute to the poor social and occupational behaviors in the patients. Recently growing evidence shows that anhedonia and amotivation are tied together, but have distinct neural correlates. It is important to note that both of these symptoms may derive from deficient functioningof the reward network. A further analysis into the neuroimaging findings of schizophrenia shows that the neural correlates overlap in the reward network including the ventral striatum, anterior cingulate cortex and orbitofrontal cortex. Other neuroimaging studies have demonstrated the involvement of the default mode network in anhedonia. The identification of aspecific deficit in hedonic and motivational capacity may help to elucidatethe mechanisms behind social functioning deficits in schizophrenia, and may also lead to more targetedtreatment of negative symptoms.
Export Options
About this article
Cite this article as:
Lee Suk Jung, Jung Suwon, Park Ho Il and Kim Jae-Jin, Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System, Current Neuropharmacology 2015; 13 (6) . https://dx.doi.org/10.2174/1570159X13666150612230333
DOI https://dx.doi.org/10.2174/1570159X13666150612230333 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Synthesis and Biological Activity of New 2,3-dihydro-1H-cyclopenta[b]- quinoline Derivatives as Acetylcholinesterase Inhibitors
Letters in Drug Design & Discovery Editorial:Advanced Methods of Biomedical Signal Processing for Early Detection of Alzheimer`s Disease
Current Alzheimer Research Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry The Prevention and Treatment of Delirium in Elderly Patients Following Hip Fracture Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Predicting Progression from Cognitive Impairment to Alzheimer’s Disease with the Disease State Index
Current Alzheimer Research Applications of Positron Emission Tomography in Neuropsychiatric Pharmaceutical Drug Development
Current Radiopharmaceuticals Isoflurane Facilitates Synaptic NMDA Receptor Endocytosis in Mice Primary Neurons
Current Molecular Medicine The Multiple Roles of Vitamin D in Human Health. A Mini-Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) In Vitro and In Vivo Neuroprotective Effects of Etifoxine in β-Amyloidinduced Toxicity Models
CNS & Neurological Disorders - Drug Targets (±)-3,5-Bis(substitutedmethyl)pyrrolidines: Application to the Synthesis of Analogues of glycine-L-proline-L-glutamic Acid (GPE)
Current Organic Synthesis Recent Developments in the Separation of Low Molecular Weight Heparin Anticoagulants
Current Medicinal Chemistry Advances in Characterization of Neuroprotective Peptide, Humanin
Current Medicinal Chemistry Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy Metabolic Syndrome and Non-Cardiac Vascular Diseases: An Update from Human Studies
Current Pharmaceutical Design Recombinant Antibody Fragments for Neurodegenerative Diseases
Current Neuropharmacology Can Transcriptomics Cut the Gordian Knot of Amyotrophic Lateral Sclerosis?
Current Genomics Diabetes-Related Neurological Implications and Pharmacogenomics
Current Pharmaceutical Design Recreational Drug Misuse and Stroke
Current Drug Abuse Reviews Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry The Early Involvement of the Innate Immunity in the Pathogenesis of Lateonset Alzheimers Disease: Neuropathological, Epidemiological and Genetic Evidence
Current Alzheimer Research